Advertisement
Screener

NIAGEN BIOSCIENCE, INC. (NAGE) Marketing Expense

2.8 / 5 stars · 68/120 Roast Me

NIAGEN BIOSCIENCE, INC. Marketing Expense

NIAGEN BIOSCIENCE, INC. (NAGE) reported Marketing Expense of $3.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:MarketingExpense · last filed 2026-08-04

  • NIAGEN BIOSCIENCE, INC. marketing expense for the quarter ending 2026-06-30 was $3.89M, a 52.09% increase year-over-year.
  • NIAGEN BIOSCIENCE, INC. marketing expense for the quarter ending 2026-03-31 was $3.52M, a 41.97% increase year-over-year.
  • NIAGEN BIOSCIENCE, INC. marketing expense for the quarter ending 2025-12-31 was $3.84M, a 48.91% increase year-over-year.
  • NIAGEN BIOSCIENCE, INC. marketing expense for the quarter ending 2025-09-30 was $2.72M, a 40.47% increase year-over-year.
  • NIAGEN BIOSCIENCE, INC. marketing expense for fiscal 2025 was $11.59M, a 35.68% increase from fiscal 2024.
  • NIAGEN BIOSCIENCE, INC. marketing expense for fiscal 2024 was $8.54M, a 16.04% increase from fiscal 2023.
  • NIAGEN BIOSCIENCE, INC. marketing expense for fiscal 2023 was $7.36M.
Period endMarketing Expense 3 monthMarketing Expense 6 monthMarketing Expense 9 monthMarketing Expense 12 month
2026-06-30$3.89M
10-Q · filed 2026-08-04
$7.41M
10-Q · filed 2026-08-04
$11.25M
derived: sum of 3 quarters · filed 2026-08-04
$13.97M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$3.52M
10-Q · filed 2026-05-06
$7.36M
derived: sum of 2 quarters · filed 2026-05-06
$10.07M
derived: sum of 3 quarters · filed 2026-05-06
$12.63M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$3.84M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04
$6.56M
derived: sum of 2 quarters · filed 2026-03-04
$9.12M
derived: sum of 3 quarters · filed 2026-08-04
$11.59M
10-K · filed 2026-03-04
2025-09-30$2.72M
10-Q · filed 2025-11-04
$5.28M
derived: sum of 2 quarters · filed 2026-08-04
$7.75M
10-Q · filed 2025-11-04
$10.33M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30$2.56M
10-Q · filed 2026-08-04
$5.04M
10-Q · filed 2026-08-04
$7.62M
derived: sum of 3 quarters · filed 2026-08-04
$9.55M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31$2.48M
10-Q · filed 2026-05-06
$5.06M
derived: sum of 2 quarters · filed 2026-05-06
$6.99M
derived: sum of 3 quarters · filed 2026-05-06
$9.11M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31$2.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04
$4.51M
derived: sum of 2 quarters · filed 2026-03-04
$6.63M
derived: sum of 3 quarters · filed 2026-03-04
$8.54M
10-K · filed 2026-03-04
2024-09-30$1.94M
10-Q · filed 2025-11-04
$4.06M
derived: sum of 2 quarters · filed 2025-11-04
$5.97M
10-Q · filed 2025-11-04
2024-06-30$2.12M
10-Q · filed 2025-08-06
$4.03M
10-Q · filed 2025-08-06
2024-03-31$1.91M
10-Q · filed 2025-05-07
2023-12-31$7.36M
10-K · filed 2025-03-04

Similar stocks

Stock NameCountryMarket CapPE Ratio
USANA HEALTH SCIENCES INC (USNA)United States$0.264B-17.90
FITLIFE BRANDS, INC. (FTLF)United States$0.087B16.59
Canopy Growth Corp (CGC)$0.395B
MANNATECH INC (MTEX)United States$0.014B
NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)United States$0.011B-1.16
Synergy CHC Corp. (SNYR)United States$0.001B
Functional Brands Inc. (MEHA)United States$0.001B
Tilray Brands, Inc. (TLRY)United States$0.554B-5.97
Cronos Group Inc. (CRON)$1.223B
Definium Therapeutics, Inc. (DFTX)United States$4.931B-17.87